Cresilon’s Traumagel, a hemostatic gel that can halt bleeding within seconds, is being considered for future applications by the Department of Defense.
While traditional bleeding control methods often involve manual pressure or using gauze and powder, Traumagel represents a significant advancement.
Approved by the FDA on Wednesday, this gel is set to revolutionize first aid for severe bleeding.
It comes in a 30-ml syringe, featuring an algae- and fungi-based gel with a consistency similar to hummus. When applied directly to a wound, it stops bleeding rapidly.
The gel is approved for moderate to severe bleeding, and its flowable nature enhances safety and efficiency, particularly in cases like gunshot wounds.
Traumagel’s approval follows the previous success of Cresilon Hemostatic Gel, a 5-ml version for minor wounds. Before this, Cresilon’s Vetigel was used extensively in veterinary practices for various procedures.
The company has leveraged its experience in veterinary medicine to prepare for Traumagel’s human use.
Cresilon has expanded its operations, including a new 33,000-square-foot manufacturing facility in Brooklyn, and is building a national sales team.
The company aims to train EMTs and physicians to use Traumagel effectively, emphasizing that the training process for humans is simpler compared to veterinary applications.
Looking ahead, Cresilon is exploring broader uses of its technology, including potential applications for stabilizing traumatic brain injuries in collaboration with the Walter Reed Army Institute of Research.
Although these applications are still in the research phase, Cresilon is focused on the upcoming launch of Traumagel and its integration into emergency medical care.
